NCT04754399

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: University of Michigan Rogel Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of Cannabidol to examine the safety and efficacy of 15 weeks of CBD in postmenopausal women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). Investigators are looking to see if patients with joint pain see improvement with the use of CBD.

Conditions

• Arthralgia
• Breast Cancer

Interventions

Type	Name	Description
DRUG	Cannabidiol (CBD)	week 1: 25 mg twice daily, approximately 12 hours apart, with food week 2: 50 mg twice daily, approximately 12 hours apart, with food week 3: 75 mg twice daily, approximately 12 hours apart, with food week 4+: 100 mg twice daily, approximately 12 hours apart, with food

Timeline

• Start date: 2021-04-16
• Primary completion: 2023-10-10
• Completion: 2023-10-10
• First posted: 2021-02-15
• Last updated: 2025-05-09
• Results posted: 2025-05-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study